GLP-1 Oral Frontier: Novo Nordisk And Eli Lilly’s 100-Year Duel Enters Its Next Chapter

Nordisk and Eli Lilly are set to reshape the oral GLP-1 market as patient demand grows and new therapies emerge. Learn more on LLY and NVO stocks here.